UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/576,296	07/15/2008	Wolfgang-Michael Franz	0286220151	4483
	7590 08/05/201 [.] LARDNER LLP	EXAMINER		
SUITE 500	——- T NIW	MERTZ, PREMA MARIA		
3000 K STREET NW WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER
			1646	
			MAIL DATE	DELIVERY MODE
			08/05/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Commence	10/576,296	FRANZ ET AL.				
Office Action Summary	Examiner	Art Unit				
	Prema M. Mertz	1646				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
	action is non-final.					
· -						
·	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
·	, , , , , , , , , , , , , , , , , , , ,					
Disposition of Claims						
4)⊠ Claim(s) <u>2-24</u> is/are pending in the application.	☑ Claim(s) <u>2-24</u> is/are pending in the application.					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.	5) Claim(s) is/are allowed.					
6)☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	☐ Claim(s) is/are objected to.					
8) Claim(s) <u>2-24</u> are subject to restriction and/or e	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
·—	· · ·					
-						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
oce the attached detailed office action for a list	or the contined copies not receive	u.				
Attachmont(s)						
Attachment(s) 1) Notice of References Cited (PTO-892)	A) T Intoniou Summary	(PTO-413)				
1) Notice of References Cited (PTO-892) A) Interview Summary (PTO-413) Discrete of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application						
Paper No(s)/Mail Date 6) LJ Other:						

DETAILED ACTION

Species Election

1a. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

administration of G-CSF before surgical or interventional procedure;

administration of G-CSF after surgical or interventional procedure; and

administration of G-CSF during surgical or interventional procedure.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Art Unit: 1646

The claims are deemed to correspond to the species listed above in the following manner:

Claims 3-6 encompasses the species.

The following claim is generic: 2.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the different administration schedules reflect different method steps and thus lack unity of invention as they do not relate to a single inventive concept.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

1b. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Art Unit: 1646

The species are as follows:

myocardial ischemia, cerebral ischemia, renal ischemia, liver ischemia, peripheral muscle tissue ischemia, retinal ischemia and spinal cord ischemia.

If myocardial ischemia is elected, election is also required to one of:

hypertension, coronary artery disease (CAD), myocardial infarction, thrombo-embolic events, trauma and/or surgical procedures.

If cerebral ischemia is elected, election is also required to one of:

trauma, stroke, thrombo-embolic events, malformation of blood-supplying vessels, multi-infarct disease, cerebral hemorrhage, surgical and/or interventional measures.

If renal ischemia is elected, election is also required to one of:

thrombo-embolic events, atherosclerosis, malformation of blood-supplying vessels, trauma and/or surgical procedures

If liver ischemia is elected, election is also required to one of:

thrombo-embolic events, malformation of blood- supplying vessels, trauma and/or surgical procedures.

If peripheral muscle tissue ischemia is elected, election is also required to one of:

Art Unit: 1646

and/or surgical procedures.

thrombo-embolic events, atherosclerosis, malformation of blood-supplying vessels, trauma and/or surgical procedures.

If retinal ischemia is elected, election is also required to one of:

thrombo-embolic events, malformation of blood- supplying vessels, trauma and/or surgical procedures.

If spinal cord ischemia is elected, election is also required to one of: thrombo-embolic events, atherosclerosis, malformation of blood-supplying vessels, trauma

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Application/Control Number: 10/576,296 Page 6

Art Unit: 1646

The claims are deemed to correspond to the species listed above in the following

manner:

Claims 7-14 encompasses the species.

The following claim(s) are generic: 2-6, 15-24.

The species listed above do not relate to a single general inventive concept under PCT

Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special

technical features for the following reasons: the different administration schedules reflect

different method steps and thus lack unity of invention as they do not relate to a single inventive

concept.

Applicant is advised that the reply to this requirement to be complete must include (i) an

election of a species or invention to be examined even though the requirement may be traversed

(37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To

preserve a right to petition, the election must be made with traverse. If the reply does not

distinctly and specifically point out supposed errors in the restriction requirement, the election

shall be treated as an election without traverse.

Advisory Information

Application/Control Number: 10/576,296

Art Unit: 1646

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on (571) 272-0835.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Prema Mertz/ Prema Mertz, Ph.D., J.D. Primary Examiner Art Unit 1646 Page 7